Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trial.

Date publication

avril 2025

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DABAKUYO-YONLI Sandrine , Pr MAYNADIE Marc

Tous les auteurs :
Wasse SK, Dabakuyo-Yonli ST, Gottlieb D, Cymbalista F, Mulligan S, Maynadie M, Aurran-Schleinitz T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40240989

Résumé

Within the French-Australian CLL6 RESIDUUM trial, an ancillary study aimed at assessing the health-related quality of life (HRQoL) of patients with chronic lymphocytic leukemia (CLL) receiving a two-year consolidation of lenalidomide (LEN) or observation (OBS) after classical immunochemotherapy leaving them with detectable residual disease.

Mots clés

Chronic lymphocytic leukemia, Clinical trial, Health-related quality of life, Lenalidomide, Patient-reported outcomes

Référence

BMC Cancer. 2025 04 16;25(1):712